Skip to content

Study · Non-randomized trial · 1998

9 results

Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.

Guzzaloni G, Grugni G, Morabito F

Minerva endocrinologica1 Dec 1998

PMID10361807 (opens in a new tab)PepBankPUB-10361807
Publisher pageAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In prepubertal short children, hexarelin 2 micrograms/kg i.v. induced a GH Cmax of 31.9 micrograms/l and an AUC of 1511 micrograms/min x l in stage I.

    In plain wordsIn short children before puberty, hexarelin raised growth hormone, with a peak of 31.9 micrograms/l in Tanner stage I.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH Cmax and AUC after hexarelin, Tanner stage I
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    GH Cmax
    31.9 micrograms/l
    stage I

    Source sentences

    Summary
    HEX induced a Cmax of 31.9 +/- 18.4 micrograms/l and an AUC of 1511 +/- 923 micrograms/min x l in stage I, of 36.7 +/- 12.3 micrograms/l and 1938 +/- 903 micrograms/min x l in stage II (ns).
  2. 02HumanNon-randomized trialEfficacy outcome

    In early pubertal short children, hexarelin 2 micrograms/kg i.v. induced a GH Cmax of 36.7 micrograms/l and an AUC of 1938 micrograms/min x l in stage II.

    In plain wordsIn short children in early puberty, hexarelin raised growth hormone, with a peak of 36.7 micrograms/l in Tanner stage II.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH Cmax and AUC after hexarelin, Tanner stage II
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    GH Cmax
    36.7 micrograms/l
    stage II

    Source sentences

    Summary
    HEX induced a Cmax of 31.9 +/- 18.4 micrograms/l and an AUC of 1511 +/- 923 micrograms/min x l in stage I, of 36.7 +/- 12.3 micrograms/l and 1938 +/- 903 micrograms/min x l in stage II (ns).
  3. 03HumanNon-randomized trialEfficacy outcome

    In short children, the GH Cmax after hexarelin was higher than after arginine plus ethinylestradiol in both stage I and stage II (p < 0.05).

    In plain wordsIn short children, hexarelin gave a higher growth hormone peak than the arginine plus estrogen test.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH Cmax versus arginine plus ethinylestradiol
    Study

    n: not reported in source

    Comparator
    Arginine plus ethinylestradiol
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    The Cmax of HEX was higher than that of ARG + E2 in both stages I and II (p < 0.05)
  4. 04HumanNon-randomized trialEfficacy outcome

    In short children, the GH AUC after hexarelin was higher than after arginine plus ethinylestradiol only in stage II (p < 0.01).

    In plain wordsIn short children, hexarelin gave a larger total growth hormone response than the arginine plus estrogen test, but only in stage II.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH AUC versus arginine plus ethinylestradiol
    Study

    n: not reported in source

    Comparator
    Arginine plus ethinylestradiol
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    AUC of HEX, was higher than that of ARG + E2 only in stage II (p < 0.01)
  5. 05HumanNon-randomized trialEfficacy outcome

    In short children, the extent of the GH response to hexarelin did not differ from the response to GHRH plus pyridostigmine.

    In plain wordsIn short children, hexarelin and the GHRH plus pyridostigmine test gave similar growth hormone responses.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH response versus GHRH plus pyridostigmine
    Study

    n: not reported in source

    Comparator
    GHRH plus pyridostigmine
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    No difference, neither in the extent of GH response to HEX and GHRH + PD nor in that to stimuli between subjects and controls, was found.
  6. 06HumanNon-randomized trialEfficacy outcome

    In children, the GH response to hexarelin did not differ between children with short stature and healthy controls.

    In plain wordsChildren with short stature and healthy children had similar growth hormone responses to hexarelin.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH response to hexarelin in short-stature subjects versus controls
    Study

    n: not reported in source

    Comparator
    Healthy age-matched controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    No difference, neither in the extent of GH response to HEX and GHRH + PD nor in that to stimuli between subjects and controls, was found.
  7. 07HumanNon-randomized trialEfficacy outcome

    In prepubertal short children, hexarelin gave 32% false positives in stage I.

    In plain wordsIn short children before puberty, the hexarelin test gave a false positive result in 32% of cases.

    Peptide
    Hexarelin
    Outcome
    Not applicableFalse positives of hexarelin test, stage I
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    False positive rate
    32%
    stage I

    Source sentences

    Summary
    HEX has given 32% false positives in stage I and 17% in stage II
  8. 08HumanNon-randomized trialEfficacy outcome

    In early pubertal short children, hexarelin gave 17% false positives in stage II.

    In plain wordsIn short children in early puberty, the hexarelin test gave a false positive result in 17% of cases.

    Peptide
    Hexarelin
    Outcome
    Not applicableFalse positives of hexarelin test, stage II
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    False positive rate
    17%
    stage II

    Source sentences

    Summary
    HEX has given 32% false positives in stage I and 17% in stage II
  9. 09HumanNon-randomized trialEfficacy outcome

    In short children, the specificity of the hexarelin test was 76%, the same as for arginine plus ethinylestradiol and below the 89% of GHRH plus pyridostigmine.

    In plain wordsIn short children, the hexarelin test had a specificity of 76%, compared with 89% for the GHRH plus pyridostigmine test.

    Peptide
    Hexarelin
    Outcome
    Not applicableSpecificity of hexarelin test
    Study

    n: not reported in source

    Comparator
    Arginine plus ethinylestradiol; GHRH plus pyridostigmine
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    Specificity
    76%
    hexarelin

    Source sentences

    Summary
    On the whole, specificity was 76% for HEX and ARG + E2 and 89% for GHRH + PD.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.